<DOC>
	<DOCNO>NCT00070538</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , VNP40101M cytarabine , use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness combine VNP40101M cytarabine treat patient hematologic malignancy , include myelodysplastic syndrome relapse , refractory , untreated leukemia .</brief_summary>
	<brief_title>VNP40101M Cytarabine Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose VP40101M administer cytarabine patient hematologic malignancy . - Determine toxic effect regimen patient . OUTLINE : This open-label , dose-escalation study VNP40101M . Patients receive cytarabine IV 24 hour day 1-4 patient 65 year age OR day 1-3 patient 65 year age . Patients also receive VNP40101M IV 15-60 minute day 2 . Treatment repeat every 4 week 3 course ( patient respond disease ) absence disease progression unacceptable toxicity . Patients continue response may receive additional course discretion investigator . Cohorts 3-6 patient receive escalate dos VNP40101M maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 10 patient may receive treatment MTD . PROJECTED ACCRUAL : Approximately 25 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis leukemia myelodysplastic syndrome ( MDS ) meeting criterion 1 follow : Relapsed refractory leukemia standard therapy anticipate result durable remission Acute myeloid leukemia Acute lymphocytic leukemia Chronic myelogenous leukemia In blast crisis Untreated leukemia standard therapy refuse Any follow poorrisk MDS : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia CNS leukemia allow PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) ALT AST great 3 time ULN Chronic hepatitis allow Renal Creatinine great 2.0 mg/dL Cardiovascular No active heart disease No myocardial infarction within past 3 month No symptomatic coronary artery disease No arrhythmia uncontrolled medication No uncontrolled congestive heart failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No persistent chronic toxic effect prior chemotherapy great grade 1 No uncontrolled active infection Infections control active treatment antibiotic allow PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 48 hour since prior hydroxyurea Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 2 week since prior myelosuppressive cytotoxic agent ( absence rapidly progress disease ) No concurrent standard investigational treatment leukemia No concurrent disulfiram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>